2023
Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol use
2021
Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study
Mahmud N, Fricker Z, Lewis JD, Taddei TH, Goldberg DS, Kaplan DE. Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Clinical Gastroenterology And Hepatology 2021, 20: e1121-e1134. PMID: 34246794, PMCID: PMC8741885, DOI: 10.1016/j.cgh.2021.06.050.Peer-Reviewed Original ResearchConceptsLiver diseasePostoperative decompensationPostoperative mortalityPostoperative infectionRisk scoreAlcohol-related liver diseaseEnd-stage liver diseaseMayo risk scoreSurgical risk scoresData of patientsMultivariable logistic regressionVeterans Health AdministrationRange of surgeryRisk prediction modelCirrhosis decompensationPugh scoreChild-TurcottePostoperative complicationsCohort studyPostoperative dayRetrospective studyStratify patientsVeteran outcomesDecompensationExcellent calibration
2019
Quality Measures, All‐Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis
Serper M, Kaplan DE, Shults J, Reese PP, Beste LA, Taddei TH, Werner RM. Quality Measures, All‐Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis. Hepatology 2019, 70: 2062-2074. PMID: 31107967, PMCID: PMC6864236, DOI: 10.1002/hep.30779.Peer-Reviewed Original ResearchConceptsHealth care useHepatocellular carcinoma surveillanceCause mortalityCare useVariceal surveillanceQuality improvement effortsPostdischarge careNational cohortSpecialty careOutpatient accessFuture quality improvement effortsLiver disease cohortUpper gastrointestinal bleedingLarge national cohortGastrointestinal bleedingMean followAdjusted analysisHigh morbidityRetrospective studyDomains of accessVeteran outcomesStandardized quality measuresInpatient careDisease cohortHigh adherenceSetting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study
Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLOS ONE 2019, 14: e0221614. PMID: 31449554, PMCID: PMC6709904, DOI: 10.1371/journal.pone.0221614.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioCost-effectiveness ratioHCC treatmentLife expectancyDifferent surveillance intervalsDecision-analytic Markov modelHepatitis C virusCause of deathAspirational scenarioCurrent HCVHCC surveillanceHCC incidenceHepatitis CSurveillance intervalsC virusCancer surveillanceVeteran outcomesLower incidenceStudy groupHCVTreatment useCirrhosisEpidemiologic studiesPatientsCompliance rate